Lee Byoung Chul, Lee Hyun Gu, Park In Ja, Kim So Yeon, Kim Ki-Hun, Lee Jae Hoon, Kim Chan Wook, Lee Jong Lyul, Yoon Yong Sik, Lim Seok-Byung, Yu Chang Sik, Kim Jin Cheon
aDivision of Colon and Rectal Surgery bDepartment of Radiology and Research Institute of Radiology cDivision of Hepatobiliary Surgery and Liver Transplantation dDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Medicine (Baltimore). 2016 Sep;95(39):e4999. doi: 10.1097/MD.0000000000004999.
We investigated recurrence pattern and oncologic outcomes after treatment of metachronous isolated liver metastases from colorectal cancer according to treatment modality.We retrospectively analyzed 123 patients treated with hepatic resection and 82 patients treated with radiofrequency ablation (RFA) for metachronous isolated hepatic metastasis from colorectal cancer (HMCRC). We compared clinicopathological data, recurrence pattern, and recurrence-free survival (RFS) rates after the treatment of hepatic metastasis between patients treated with RFA and resection.The patients in the 2 groups were similar in gender, location of primary tumor, disease-free interval to hepatic metastasis, pathologic stage of primary tumor, and number of hepatic metastasis. The age was older in RFA group but it was not statistically different. The mean diameter of the largest hepatic mass was greater in the resection group than in the RFA group (3.1 vs 1.9 cm, P < 0.001). Chemotherapy after the treatment of hepatic metastasis was more commonly given in hepatic resection group (76.4% vs 62.2%, P = 0.04). Recurrence after the treatment of hepatic metastasis was not significantly different between the 2 groups (54.5% vs 65.9% in the resection and RFA groups). However, intrahepatic recurrence without extra-hepatic metastases was more common in the RFA group than in the resection group (47.5% vs 12.1%, P < 0.001). The RFS rate after the treatment of hepatic metastasis was significantly higher in resection group (48.6% vs 33.7%, P = 0.015). The size and number of hepatic metastasis, primary tumor stage, disease-free interval to hepatic metastasis, and the modality of treatment (RFA vs resection) for hepatic metastasis were confirmed as associated factors with re-recurrence after the treatment of hepatic metastasis. Among patients with solitary hepatic metastases of ≤3 cm, marginal recurrence was higher in the RFA group (3% vs 17.2%) and re-RFA was performed to achieve comparable recurrence rate (3% vs 5.2%, P = 0.662), the RFS rate was not different between the resection and RFA group (52.4% vs 53.4%, P = 0.491).Surgical resection for HMCRC showed higher RFS. However, the RFS rate in patients with a solitary hepatic metastasis of ≤3 cm was similar between the resection and RFA groups.
我们根据治疗方式,对结直肠癌异时性孤立性肝转移瘤治疗后的复发模式和肿瘤学结局进行了研究。我们回顾性分析了123例接受肝切除术治疗以及82例接受射频消融(RFA)治疗的结直肠癌异时性孤立性肝转移瘤(HMCRC)患者。我们比较了接受RFA治疗和肝切除术治疗的患者在肝转移瘤治疗后的临床病理数据、复发模式和无复发生存(RFS)率。两组患者在性别、原发肿瘤位置、至肝转移瘤的无病间期、原发肿瘤的病理分期以及肝转移瘤数量方面相似。RFA组患者年龄较大,但差异无统计学意义。肝切除组最大肝肿块的平均直径大于RFA组(3.1 cm对1.9 cm,P<0.001)。肝转移瘤治疗后,肝切除组更常给予化疗(76.4%对62.2%,P = 0.04)。两组肝转移瘤治疗后的复发率无显著差异(肝切除组和RFA组分别为54.5%和65.9%)。然而,RFA组肝内复发且无肝外转移比肝切除组更常见(47.5%对12.1%,P<0.001)。肝转移瘤治疗后的RFS率在肝切除组显著更高(48.6%对33.7%,P = 0.015)。肝转移瘤的大小和数量、原发肿瘤分期、至肝转移瘤的无病间期以及肝转移瘤的治疗方式(RFA对肝切除术)被确认为肝转移瘤治疗后再次复发的相关因素。在孤立性肝转移瘤直径≤3 cm的患者中,RFA组边缘复发更高(3%对17.2%),并进行了再次RFA以达到相似的复发率(3%对5.2%,P = 0.662),肝切除组和RFA组的RFS率无差异(52.4%对53.4%,P = 0.491)。HMCRC的手术切除显示出更高的RFS。然而,孤立性肝转移瘤直径≤3 cm的患者中,肝切除组和RFA组的RFS率相似。